Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Vascular Permeability Factor, Etc.); Or Binds Serum Protein, Plasma Protein, Fibrin, Or Enzyme Patents (Class 424/158.1)
  • Patent number: 10408847
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: September 10, 2019
    Assignee: SomaLogic, Inc.
    Inventors: Urs Ochsner, David G. Sterling, Nebojsa Janjic
  • Patent number: 10400036
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 10400035
    Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 3, 2019
    Assignees: MedImmune, LLC, University of Helsinki
    Inventors: Kari Alitalo, Simo Syrjala, Karl Lemstrom, Ching Ching Leow, Ronald Herbst, Jane Connor
  • Patent number: 10385127
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 20, 2019
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Patent number: 10376813
    Abstract: The present invention relates to a method for the determination of chromatography conditions for the separation of a biomolecule from a liquid sample, which method comprises selecting a number of experiments using design of experiments (DoE); performing said experiments with in-line conditioning of orthogonal quality measures; and based on the results from the experiments, determining efficient chromatography conditions for said biomolecule. The invention also relates to a system for performing the method as well as a computer program and an instrument comprising such a computer program.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 13, 2019
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Enrique Napoleon Carredano, Gustav Jose Rodrigo
  • Patent number: 10376582
    Abstract: The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: August 13, 2019
    Assignee: Outlook Therapeutics, Inc.
    Inventors: John Cini, Athena Nagi, Maria Taddei
  • Patent number: 10358498
    Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: July 23, 2019
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company, Limited
    Inventors: Reimar Abraham, Keisuke Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
  • Patent number: 10351623
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 16, 2019
    Assignees: Orega Biotech, Institut National de la Sante et de La Recherche Medicale (INSERM)
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Patent number: 10330670
    Abstract: Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: June 25, 2019
    Assignees: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, JAPAN INNOVATION THERAPEUTICS, INC.
    Inventors: Hiroshi Matsuda, Akane Tanaka
  • Patent number: 10287345
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Patent number: 10273298
    Abstract: The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: April 30, 2019
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Gesche Graf
  • Patent number: 10259859
    Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 16, 2019
    Assignee: ALX ONCOLOGY INC.
    Inventors: Jaume Pons, Laura Deming, Corey Goodman, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
  • Patent number: 10189899
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: January 29, 2019
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • Patent number: 10111953
    Abstract: The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 30, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gary Swergold, William J. Sasiela, Robert C. Pordy
  • Patent number: 10081680
    Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. Antibodies that are bispecific for SIRP? and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 25, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kipp Andrew Weiskopf, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman, Nan Guo Ring
  • Patent number: 10059764
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: August 28, 2018
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Patent number: 10029016
    Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 24, 2018
    Assignee: Massachusetts Insitute of Technology
    Inventors: Darrell Irvine, Haipeng Liu
  • Patent number: 10023654
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 17, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
  • Patent number: 9975945
    Abstract: The invention relates to a composition comprising immunoglobulins specific to influenza virus and produced through immunization of a producer animal, for use as a medicament for the passive immunization of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus and/or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 ?g of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: May 22, 2018
    Assignee: FABENTECH
    Inventors: Bertrand Lepine, Laurent Vacher, Caroline Durand, Cécile Herbreteau-Delale
  • Patent number: 9956244
    Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: May 1, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Ji Min Lee, Bo Gyou Kim, Seung Ja Oh, Kyung Ah Kim, Saet Byoul Lee, Jae Woong Hwang
  • Patent number: 9944704
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 9918822
    Abstract: A method of stimulating a renal nerve in a human patient comprising, selecting a span of renal artery in the patient for implantation of a self-expanding stent, the artery having a first internal diameter, an artery wall, and being surrounded by peri-adventitial space through which at least one renal nerve extends; measuring the first internal diameter; selecting a self-expanding stent configured to be capable of expanding to have a second diameter that, in an expanded condition once implanted within the artery, is between 2 mm and 4 mm larger than the first diameter; implanting the stent in the span of the renal artery, whereby the stent eventually expands to the second diameter and thereby passes through the artery wall to become embedded in peri-advential space; and at least partially blocking the renal nerve or modulating a function of the nerve.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: March 20, 2018
    Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventors: Chad Abunassar, Erik D. Eli, Denis Tauz
  • Patent number: 9914769
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: March 13, 2018
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 9902986
    Abstract: The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: February 27, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Elizabeth Marie Nolan, Tengfei Zheng, Phoom Chairatana
  • Patent number: 9803026
    Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 31, 2017
    Assignee: SBI Biotech Co., Ltd.
    Inventors: Tomohide Yamazaki, Jing Zhao, Koji Ishida, Yasue Shibata, Minkwon Cho, Mayuki Endo
  • Patent number: 9690975
    Abstract: Techniques are described for determining the quality of a nerve graft by assessing quantitative structural characteristics of the nerve graft. Aspects of the techniques include obtaining an image identifying laminin-containing tissue in the nerve graft; creating a transformed image using a transformation function of an image processing application on the image; using an analysis function of the image processing application, analyzing the transformed image to identify one or more structures in accordance with one or more recognition criteria; and determining one or more structural characteristics of the nerve graft derived from a measurement of the one or more structures.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: June 27, 2017
    Assignee: AXOGEN CORPORATION
    Inventor: Curt Deister
  • Patent number: 9683038
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 20, 2017
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Patent number: 9650429
    Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 16, 2017
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventor: Suzanne Ostrand-Rosenberg
  • Patent number: 9637543
    Abstract: Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 2, 2017
    Assignees: THE UAB RESEARCH FOUNDATION, BEIJING COTIMES BIOTECH CO., LTD.
    Inventors: Tong Zhou, Donald J. Buchsbaum, Enyun Shen, Xian Chen
  • Patent number: 9598487
    Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: March 21, 2017
    Assignee: ESBATech, an Alcon Biomedical Unit LLC
    Inventors: Leonardo Jose Borras, David Urech
  • Patent number: 9574004
    Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: February 21, 2017
    Assignees: Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc.
    Inventors: Marius Ardeleanu, Namita A. Gandhi, Neil Graham, Stephanie C. Kirkesseli, Sudeep Kundu, Ross E. Rocklin, Allen Radin, Steven P. Weinstein, Jennifer Davidson Hamilton, Jeffrey Ming
  • Patent number: 9546215
    Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 17, 2017
    Assignee: ALLAKOS INC.
    Inventors: Christopher R. Bebbington, Rustom Falahati, Carolina Rita Sousa Fernandes, David John Matthews, Nenad Tomasevic, Jason Williams, John Leung
  • Patent number: 9540449
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present invention includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies of the invention, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: January 10, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: George D. Yancopoulos, Nicholas J. Papadopoulos, Andrew J. Murphy, Neil Stahl
  • Patent number: 9448229
    Abstract: The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 20, 2016
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Mi-La Cho, Chul-Woo Yang, Jong-Young Choi, Joo-Yeon Jhun, Hee-Yeon Kim, Jae-Kyeong Byun, Ye-Been Yim, Byung-Ha Chung, Kyoung-Woon Kim
  • Patent number: 9365646
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: June 14, 2016
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Patent number: 9358288
    Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: June 7, 2016
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michael Sela, Yosef Yarden, Bilha Schechter, Tsipi Ben-Kasus
  • Patent number: 9339484
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.
    Type: Grant
    Filed: February 16, 2013
    Date of Patent: May 17, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9321773
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 26, 2016
    Assignee: Respivert, Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • Patent number: 9308275
    Abstract: The preset invention provides a method of increasing the effect of an activated-potentiated form of an antibody to an endogenous biological molecule by combining said endogenous biological molecule with an activated-potentiated form of an antibody to endothelial NO-synthase. The present invention also provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to an endogenous biological molecule, and b) an activated-potentiated form of an antibody to NO synthase.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: April 12, 2016
    Inventor: Oleg Iliich Epshtein
  • Patent number: 9220781
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: December 29, 2015
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 9212222
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 15, 2015
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Jaume Pons, Arnon Rosenthal
  • Patent number: 9193801
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: November 24, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Patent number: 9163083
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: October 20, 2015
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
  • Patent number: 9121858
    Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: September 1, 2015
    Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine, Centre Hospaitalier et de Nancy (CHU), Universite Paris Descartes
    Inventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad
  • Publication number: 20150147341
    Abstract: There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Publication number: 20150147342
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Israel Lowy, Gavin Thurston, Christopher Daly
  • Publication number: 20150147335
    Abstract: The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treating hidradenitis suppurativa in a subject.
    Type: Application
    Filed: May 28, 2014
    Publication date: May 28, 2015
    Inventors: Martin M. Okun, Thomas C. Harris
  • Publication number: 20150147340
    Abstract: Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided. In one aspect, the present invention provides a method of treating a subject with peritoneal carcinomatosis, the method comprises the administration to the subject of an effective amount ohm anti-connective tissue growth factor (CTGF) agent, thereby treating the peritoneal carcinomatosis. In some embodiments, the peritoneal carcinomatosis results from a cancer selected from the group consisting of gall bladder cancer, bile duct cancer, liver cancer, colon cancer, cancer of the appendix, ovarian cancer, fallopian tube cancer, bladder cancer, pancreatic cancer, mesothelioma, rectal cancer, small bowel cancer and stomach cancer. In particular embodiments, the cancer is ovarian cancer.
    Type: Application
    Filed: March 12, 2013
    Publication date: May 28, 2015
    Inventors: Goli Samimi, Kim Moran-Jones
  • Publication number: 20150147326
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 28, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki University
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20150140010
    Abstract: The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine protein kinase (CASK) in a blood sample obtained from the subject. The present invention also relates to an agent effective to inhibit the binding of CASK to hCD98 present on the surface of podocytes for use in the prevention or treatment of focal segmental glomerulosclerosis (FSGS) in a subject in need thereof.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Applicants: INSERM 9INSTITUT NATIONAL DE LA SANTE ET DE LA R- ECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Antoine Durrbach, Hanz Lorenzo, Severine Beaudreuil